Baxter International (BAX) → Stock, financial statements
Advertising

Baxter International

72.6 USD +0.30 (+0.38%)
May 19 🇺🇸 NYSE BAX
Dividends News
Favorites
  • BAX Ticker
  • 🇺🇸 NYSE Exchange
  • 50,000 Employees
3 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements — Baxter International

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 20 2020
Total Revenue
12B
Cost Of Revenue
7.1B
Gross Profit
4.6B
Research and Development
520M
Selling General and Admin
2.5B
Operating Expense
10B
Operating Income
1.6B
Other Income Expense Net
0
EBIT
1.6B
Interest Income
130M
Pretax Income
1.3B
Income Tax
180M
Minority Interest
8M
Net Income
1.1B
Net Income Basic
1.1B
20 ← 20 2020
Current cash
3.7B
Short term investments
690M
Receivables
2.1B
Inventory
1.9B
Other current assets
690M
Current assets
8.4B
Long term investments
12B
Property plant equipment
4.7B
Goodwill
3.2B
Intangible assets
1.7B
Other assets
510M
Total assets
20B
Accounts payable
1B
Current long term debt
410M
Other current liabilities
1.9B
Total current liabilities
3.3B
Long term debt
5.8B
Other liabilities
1.5B
Minority Interest
37M
Total Liabilities
11B
Common stock
510M
Retained earning
16B
Treasury stock
-11B
Capital surplus
Shareholder equity
8.7B
Net tangible assets
3.8B
20 ← 20 2020
Net Income
1.1B
Depreciation
820M
Changes in receivables
180M
Changes in inventories
260M
Cash change
400M
Cash flow
1.9B
Capital expenditures
-710M
Investments
Investing activity other
Total investing cash flows
-1.2B
Dividends paid
Net borrowings
1.8B
Other financing cash flows
Cash flow financing
-350M
Exchange rate effect

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.